Safety and efficacy of valbenazine for the treatment of chorea associated with Huntington's disease (KINECT-HD): a phase 3, randomised, double-blind, placebo-controlled trial (vol 22, pg 494, 2023)

被引：0
|
作者：
Granit, V
Benatar, M.
Kurtoglu, M.
机构：
来源：
LANCET NEUROLOGY | 2023年 / 22卷 / 09期
关键词：
D O I：
10.1016/S1474-4422(23)00282-X
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：E10 / E10
页数：1
相关论文
共 50 条
  • [41] Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial (vol 8, pg 963, 2020)
    Khanna, D.
    Lin, C. J. F.
    Furst, D. E.
    LANCET RESPIRATORY MEDICINE, 2020, 8 (10): : E75 - E75
  • [42] Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial (vol 8, pg 963, 2020)
    Khanna, Dinesh
    Lin, Celia J. F.
    Furst, Daniel E.
    Goldin, Jonathan
    Kim, Grace
    Kuwana, Masataka
    Allanore, Yannick
    Matucci-Cerinic, Marco
    Distler, Oliver
    Shima, Yoshihito
    van Laar, Jacob M.
    Spotswood, Helen
    Wagner, Bridget
    Siegel, Jeffrey
    Denton, Christopher P.
    LANCET RESPIRATORY MEDICINE, 2021, 9 (03): : E29 - E29
  • [43] Randomised placebo-controlled double-blind trial to assess safety and efficacy of erythropoietin in patients with Friedreich's ataxia
    Mariotti, C.
    Fancellu, R.
    Nanetti, L.
    Solari, A.
    Martini, A.
    Di Bella, D.
    Plumari, M.
    Lauria, G.
    Cappellini, M. D.
    Taroni, F.
    JOURNAL OF NEUROLOGY, 2008, 255 : 65 - 66
  • [44] Efficacy and Safety of Omilancor in a Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial of Patients With Crohn's Disease
    Chowla, Navreet M.
    Tariq, Raseen
    Aggarwal, Manik
    Loftus, Edward V.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2023, 118 (10): : S820 - S821
  • [45] Efficacy and safety of valbenazine in Japanese patients with tardive dyskinesia: A multicenter, randomized, double-blind, placebo-controlled study (J-KINECT)
    Horiguchi, Jun
    Watanabe, Koichiro
    Kondo, Kazuoki
    Iwatake, Atsushi
    Sakamoto, Hajime
    Susuta, Yutaka
    Masui, Hideaki
    Watanabe, Yumi
    PSYCHIATRY AND CLINICAL NEUROSCIENCES, 2022, 76 (11) : 560 - 569
  • [46] Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial (vol 15, pg 966, 2014)
    van Rhee, F.
    Wong, R. S.
    Munshi, N.
    LANCET ONCOLOGY, 2014, 15 (10): : E417 - E417
  • [47] Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial
    Rovin, Brad H.
    Teng, Y. K. Onno
    Ginzler, Ellen M.
    Arriens, Cristina
    Caster, Dawn J.
    Romero-Diaz, Juanita
    Gibson, Keisha
    Kaplan, Joshua
    Lisk, Laura
    Navarra, Sandra
    Parikh, Samir V.
    Randhawa, Simrat
    Solomons, Neil
    Huizinga, Robert B.
    LANCET, 2021, 397 (10289): : 2070 - 2080
  • [48] Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial
    Khanna, Dinesh
    Lin, Celia J. F.
    Furst, Daniel E.
    Goldin, Jonathan
    Kim, Grace
    Kuwana, Masataka
    Allanore, Yannick
    Matucci-Cerinic, Marco
    Distler, Oliver
    Shima, Yoshihito
    van Laar, Jacob M.
    Spotswood, Helen
    Wagner, Bridget
    Siegel, Jeffrey
    Jahreis, Angelika
    Denton, Christopher P.
    LANCET RESPIRATORY MEDICINE, 2020, 8 (10): : 963 - 974
  • [49] Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial
    van Rhee, Frits
    Wong, Raymond S.
    Munshi, Nikhil
    Rossi, Jean-Francois
    Ke, Xiao-Yan
    Fossa, Alexander
    Simpson, David
    Capra, Marcelo
    Liu, Ting
    Hsieh, Ruey Kuen
    Goh, Yeow Tee
    Zhu, Jun
    Cho, Seok-Goo
    Ren, Hanyun
    Cavet, James
    Bandekar, Rajesh
    Rothman, Margaret
    Puchalski, Thomas A.
    Reddy, Manjula
    van de Velde, Helgi
    Vermeulen, Jessica
    Casper, Corey
    LANCET ONCOLOGY, 2014, 15 (09): : 966 - 974
  • [50] Efficacy and safety of garadacimab, a factor XIIa inhibitor for hereditary angioedema prevention (VANGUARD): a global, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial (vol 401, pg 1079, 2023)
    Craig, T. J.
    Reshef, A.
    Li, H. H.
    LANCET, 2023, 401 (10384): : 1266 - 1266
12345